RNAZ SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2026

10-K/A

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Apr 30, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Apr 15, 2026

NT 10-K

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Mar 31, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

TransCode Therapeutics Retains Tungsten Advisors for Formal Strategic Process to Maximize Portfolio Value

Oct 28, 2026

8-K

TransCode Therapeutics Executes Waiver and Prepayment Agreement with Yorkville for Convertible Notes

Oct 1, 2026

8-K

TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Phase 1a Trial

Sep 28, 2026

8-K

TransCode Therapeutics Announces CFO Resignation and Appointment of Interim CFO

Sep 11, 2026

8-K

TransCode Therapeutics Files Second Amended and Restated Certificate of Designation for Preferred Stock

Aug 3, 2026

8-K

TransCode Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jul 20, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Jul 20, 2026

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Jul 20, 2026

424B5

REGISTERED OFFERING

Mar 25, 2025

424B5

Jul 24, 2024

424B5

Shares of Common Stock

Jul 22, 2024

424B4

Jan 19, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-1

SPA | Shares: 1,533,334

Apr 30, 2026

S-3

SHARE RESALE REGISTRATION

Apr 30, 2026

S-3

December 2025 SHELF

Dec 12, 2025

Form D - Notice of Exempt Offering of Securities - Item 06b

Dec 12, 2024

S-1

Form S-1 - General form for registration of securities under the Securities Act of 1933

Dec 6, 2024

S-1/A

INITIAL REGISTRATION FOR OFFERING | Shares amount: 3,472,222 | Share price: $2.16 | Warrants amount: 6,944,444 EFFECTIVE

Jan 18, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jul 17, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jun 2, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 26, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

May 8, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 7, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 3, 2026

Ownerships

TYPE

HEADLINE

FILED AT

Tattory John A (Reporting)

Sep 21, 2026

Fitzgerald Thomas A (Reporting)

Sep 11, 2026

CK Life Sciences Intl (Holdings) Inc (Reporting)

Aug 5, 2026

CK Life Sciences Intl (Holdings) Inc (Reporting)

Aug 5, 2026

SCHEDULE 13D/A

CK Life Sciences Intl (Holdings) Inc (Filed by)

Aug 3, 2026

SCHEDULE 13G

Unleash Immuno Oncolytics, Inc. (Filed by)

Jul 28, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 20, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

May 20, 2026

CORRESP

Form CORRESP - Correspondence

May 15, 2026

CORRESP

Form CORRESP - Correspondence

May 15, 2026

LETTER

Form UPLOAD - SEC-generated letter

May 6, 2026

LETTER

Form UPLOAD - SEC-generated letter

May 6, 2026

TransCode Therapeutics, Inc. RNAZ · SEC Filings